Sugi Predict

Sugi Predict / Targets / L1CAM

L1CAM

Neural cell adhesion molecule L1 · P32004 · L1CAM on Sugi Atlas →

227 patent compounds predicted against L1CAM, 217 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL77381 SCHEMBL77381 0.71 1/20
SCHEMBL28850791 SCHEMBL28850791 0.69 1/20
SCHEMBL8722405 SCHEMBL8722405 0.63 1/20
SCHEMBL6636585 SCHEMBL6636585 0.62 1/20
SCHEMBL1169719 SCHEMBL1169719 0.61 1/20
SCHEMBL4218154 SCHEMBL4218154 0.61 1/20
Potassium Ion Potassium Ion (SCHEMBL4755324) 0.61 1/20
SCHEMBL6638020 SCHEMBL6638020 0.61 1/20
Potassium Ion Potassium Ion (SCHEMBL11808886) 0.61 1/20
SCHEMBL23978398 SCHEMBL23978398 0.61 1/20
SCHEMBL29851354 SCHEMBL29851354 0.61 1/20
SCHEMBL6448644 SCHEMBL6448644 0.59 1/20
SCHEMBL8015608 SCHEMBL8015608 0.58 1/20
SCHEMBL5456246 SCHEMBL5456246 0.57 1/20
SCHEMBL6451494 SCHEMBL6451494 0.57 1/20
Potassium Ion Potassium Ion (SCHEMBL29123377) 0.56 1/20
SCHEMBL6633920 SCHEMBL6633920 0.56 1/20
SCHEMBL6634684 SCHEMBL6634684 0.56 1/20
SCHEMBL28721042 SCHEMBL28721042 0.56 1/20
SCHEMBL30912997 SCHEMBL30912997 0.56 1/20

Clinical trials — most relevant to L1CAM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome PHASE2COMPLETED
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
B7-H3 CAR-T for Recurrent or Refractory Glioblastoma PHASE1/PHASE2UNKNOWN
CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer PHASE1/PHASE2UNKNOWN
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis PHASE2COMPLETED
Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer PHASE2UNKNOWN
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma PHASE1/PHASE2RECRUITING
The Synapse Project PHASE2COMPLETED
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors PHASE1NOT_YET_RECRUITING
Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry nanACTIVE_NOT_RECRUITING
Marker of Brain Insulin Resistance in AD Prognosis nanNOT_YET_RECRUITING
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis nanRECRUITING
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients nanCOMPLETED
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Study of CIDP Patients During IVIG Treatment nanCOMPLETED
Comparison of Two Non-invasive Neuromodulation Techniques as Synergistic Therapy to Cognitive Stimulation in Amnestic Mild Cognitive Impairment (aMCI) nanRECRUITING
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury nanCOMPLETED
p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram nanCOMPLETED
The Clinical Impact of the Novel Alzheimer's Blood-based Biomarkers nanUNKNOWN
The Cognitive-Behavioral Dysfunctions and the Potential of Neuroplasticity in Brain Tumors Patients During Radiotherapy nanUNKNOWN
Imaging Genetics of Laryngeal Dystonia nanRECRUITING
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy nanRECRUITING
Noninvasive Evaluation of Cardiac Allograft Vasculopathy nanWITHDRAWN
Noninvasive Predictors of Transplant Vasculopathy nanWITHDRAWN
Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease nanUNKNOWN
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a L1CAM binder may also engage these)

ProteinNameSimilarity
Q05695 — 1.000 Q05695 →
P11627 — 1.000 P11627 →
Q92823 — 0.994 Q92823 →
Q8AV58 — 0.994 Q8AV58 →
P97686 — 0.993 P97686 →
Q3UH53 — 0.993 Q3UH53 →
Q8AV57 — 0.991 Q8AV57 →
Q810U4 — 0.990 Q810U4 →
Q7Z5N4 — 0.989 Q7Z5N4 →
Q6V4S5 — 0.989 Q6V4S5 →
P70232 — 0.988 P70232 →
O00533 — 0.987 O00533 →
Q8AXZ4 — 0.985 Q8AXZ4 →
Q02246 — 0.984 Q02246 →
Q9QZS7 — 0.984 Q9QZS7 →
Q58EX2 — 0.984 Q58EX2 →
O94856 — 0.984 O94856 →
Q61330 — 0.984 Q61330 →
O55005 — 0.983 O55005 →
Q9Y6N7 — 0.983 Q9Y6N7 →
P28685 — 0.982 P28685 →
Q64604 — 0.982 Q64604 →
Q9R044 — 0.982 Q9R044 →
P35331 — 0.981 P35331 →
P22063 — 0.981 P22063 →
Q9ERC8 — 0.981 Q9ERC8 →
Q8VHZ8 — 0.981 Q8VHZ8 →
Q32MD9 — 0.980 Q32MD9 →
Q63198 — 0.980 Q63198 →
F1NY98 — 0.980 F1NY98 →